Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis.

Blood cancer journal·2026
Same author

The ratio of brain to liver glucose activity and prognosis with CAR-T in non-Hodgkin lymphoma.

Blood cancer journal·2025
Same author

EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity.

Blood cancer journal·2025
Same author

Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.

American journal of hematology·2025
Same author

Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience.

Blood advances·2025
Same author

Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.

American journal of hematology·2025

Related Experiment Video

Updated: Oct 2, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.

Arushi Khurana1, Yi Lin2

  • 1Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA.

Current Treatment Options in Oncology
|February 25, 2022
PubMed
Summary

Allogeneic CAR-T therapies offer an accessible, standardized alternative to autologous treatments for non-Hodgkin lymphoma. Genomic editing is key to overcoming challenges like graft-versus-host disease for universal CAR-T application.

Keywords:
Allogeneic CAR-TCAR-TNon-Hodgkin lymphoma

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Related Experiment Videos

Last Updated: Oct 2, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.5K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Area of Science:

  • Immunotherapy
  • Oncology
  • Genomic Editing

Background:

  • Chimeric antigen receptor T cell (CAR-T) therapies have advanced non-Hodgkin lymphoma (NHL) treatment.
  • Autologous CAR-T therapies face limitations including manufacturing delays and variable quality.

Purpose of the Study:

  • To review strategies for developing allogeneic CAR-T therapies.
  • To discuss cell sources and current clinical experiences with allogeneic CAR-T in lymphoma.

Main Methods:

  • Review of current literature on allogeneic CAR-T development.
  • Analysis of genomic editing tools (TALEN, CRISPR) for CAR-T applications.
  • Examination of early-phase clinical trial data for allogeneic CAR-T in lymphoma.

Main Results:

  • Allogeneic CAR-T therapies present an "off the shelf" solution with standardized quality.
  • Genomic editing is crucial for allogeneic CAR-T to prevent graft-versus-host disease and allo-rejection.
  • Early clinical trial data for allogeneic CAR-T in lymphoma show encouraging preliminary results.

Conclusions:

  • Allogeneic CAR-T therapies hold promise for improved accessibility and quality in lymphoma treatment.
  • Further long-term follow-up is necessary to establish the safety and feasibility of allogeneic CAR-T.
  • Advancements in genomic editing are pivotal for realizing universal, off-the-shelf CAR-T products.